References
- Bhat TN, Bentley GA, Fischmann TO, Boulot G, Poljak RJ. 1990. Small rearrangements in structures of Fv and Fab fragments of antibody D1.3 on antigen binding. Nature 347:483–485
- Brockmann EC, Akter S, Savukoski T, Huovinen T, Lehmusvuori A, Leivo J, Saavalainen O, et al. 2011. Synthetic single-framework antibody library integrated with rapid affinity maturation by VL shuffling. Protein Eng Des Sel 24:691–700
- Couchman JR. 2009. Commercial antibodies: The good, bad, and really ugly. J Histochem Cytochem: J Histochem Soc 57:7–8
- Himanen JP, Rajashankar KR, Lackmann M, Cowan CA, Henkemeyer M, Nikolov DB. 2001. Crystal structure of an Eph receptor-ephrin complex. Nature 414:933–938
- Himanen JP, Chumley MJ, Lackmann M, Li C, Barton WA, Jeffrey PD, Vearing C, et al. 2004. Repelling class discrimination: Ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci 7:501–509
- Himanen JP, Goldgur Y, Miao H, Myshkin E, Guo H, Buck M, Nguyen M, et al. 2009. Ligand recognition by A-class Eph receptors: Crystal structures of the EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex. EMBO Rep 10:722–728
- Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC. 1998. Antibody phage display technology and its applications. Immunotechnol: Int J Immunol Eng 4:1–20
- Huovinen T, Syrjanpaa M, Sanmark H, Brockmann EC, Azhayev A, Wang Q, Vehniainen M, Lamminmaki U. 2013. Two ScFv antibody libraries derived from identical VL-VH framework with different binding site designs display distinct binding profiles. Protein Eng Des Sel 26:683–693
- Jones TA, Zou JY, Cowan SW, Kjeldgaard M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110–119
- Kankaanpaa P, Paavolainen L, Tiitta S, Karjalainen M, Paivarinne J, Nieminen J, Marjomaki V, et al. 2012. BioImageXD: An open, general-purpose and high-throughput image-processing platform. Nat Methods 9:683–689
- Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
- Long F, Vagin AA, Young P, Murshudov GN. (2008). BALBES: a molecular-replacement pipeline. Acta Crystallographica D, 64:125–132
- Murshudov G N, Vagin, AA, Dodson, E. J. (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallographica D 53:240–255
- Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, et al. 2011. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147:554–564
- Paino A, Ahlstrand T, Nuutila J, Navickaite I, Lahti M, Tuominen H, Valimaa H, et al. 2013. Identification of a novel bacterial outer membrane interleukin-1beta-binding protein from aggregatibacter actinomycetemcomitans. PLoS One 8:e70509
- Rock EP, Sibbald PR, Davis MM, Chien YH. 1994. CDR3 length in antigen-specific immune receptors. J Exp Med 179:323–328
- Saper CB. 2005. An open letter to our readers on the use of antibodies. J Comp Neurol 493:477–478
- Siddiqui MZ. 2010. Monoclonal antibodies as diagnostics; an appraisal. Indian J Pharmaceut Sci 72:12–17
- Sliwkowski MX, Mellman I. 2013. Antibody therapeutics in cancer. Science 341:1192–1198
- Stern M, Herrmann R. 2005. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol/Hematol 54:11–29
- Yagami H, Kato H, Tsumoto K, Tomita M. 2013. Monoclonal antibodies based on hybridoma technology. Pharmaceut Pat Anal 2:249–263
- Zdanov A, Li Y, Bundle DR, Deng SJ, MacKenzie CR, Narang SA, Young NM, Cygler M. 1994. Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution. Proc Natl Acad Sci USA 91:6423–6427